The world's first bivalent mRNA vaccine candidate against the respiratory syncyt...

The world's first bivalent mRNA vaccine candidate against the respiratory syncytial virus, or RSV, began Phase I clinical trial at a major Shanghai hospital in China on Wednesday.

The developer of the vaccine candidate said that the adult participant was in stable condition and under medical observation after the vaccination.